Lupin has informed that it enclosed a Press Release as regards, receipt of the Establishment Inspection Report from U.S. FDA for the Company's Somerset. NJ manufacturing facility, inspection of which was carried out in March 2022. The U.S. FDA has determined that the inspection classification of the facility is Voluntary Action Indicated. This may be considered as a disclosure pursuant to Regulation 30 of SEBI Listing Obligations and Disclosure Requirements) Regulations, 2015.
The above information is a part of company’s filings submitted to BSE.
